We are focused on the treatment of hemophilia using our high potency coagulation factors that promote blood clotting. A clinical trial of our Factor IX candidate in individuals with hemophilia B was initiated in June of 2017. We also plan to initiate an efficacy clinical trial of our Factor VIIa candidate in individuals with hemophilia and inhibitors in the fourth quarter of 2017.
Next Generation Hemostasis Programs
*(formerly known as CB 813d)
|Anti-C3: CB 2782||Renal Delayed Graft Function (DGF), Ischemia/Reperfusion Injury (IRI) Cardiovascular|
|Anti-C3: Ophthalmic||Dry Age-related Macular Degeneration (AMD)|